| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | - | - | 6.915 | 2.358 | 22.798 | 23.268 | 31.856 | 83.110 |
| Total Income - EUR | - | - | - | - | 6.915 | 2.358 | 22.798 | 24.130 | 32.954 | 83.110 |
| Total Expenses - EUR | - | - | - | - | 0 | 88 | 1.135 | 1.121 | 9.039 | 9.357 |
| Gross Profit/Loss - EUR | - | - | - | - | 6.915 | 2.269 | 21.664 | 23.009 | 23.915 | 73.752 |
| Net Profit/Loss - EUR | - | - | - | - | 6.708 | 2.199 | 20.980 | 22.445 | 23.596 | 72.311 |
| Employees | - | - | - | - | 0 | 0 | 0 | 1 | 1 | 1 |
Check the financial reports for the company - Uro - Onco Med S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | - | - | 0 | 0 | 0 | 1.727 | 433 | 0 |
| Current Assets | - | - | - | - | 6.957 | 8.841 | 11.378 | 26.524 | 42.928 | 79.298 |
| Inventories | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | - | - | - | - | 6.915 | 6.784 | 8.819 | 24.349 | 36.079 | 75.850 |
| Cash | - | - | - | - | 42 | 2.056 | 2.558 | 2.175 | 6.848 | 3.448 |
| Shareholders Funds | - | - | - | - | 6.750 | 8.829 | 9.873 | 22.494 | 32.211 | 72.351 |
| Social Capital | - | - | - | - | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | - | - | - | - | 207 | 12 | 1.505 | 5.758 | 11.150 | 6.947 |
| Income in Advance | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8622 - 8622" | |||||||||
| CAEN Financial Year |
8622
|
|||||||||
Comments - Uro - Onco Med S.r.l.